medtechdive5d
Exact Sciences’ forecast cut shocks analysts
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
GE Healthcare Earnings: No Visibility on Timing of China Rebound, but Margin Improvement Intact
We think steady margin improvement will continue over the next few years as management optimizes its operations as a ...
Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product. The analyst ...
Investing15d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.
Business Insider16d
Exact Sciences price target raised to $95 from $75 at Canaccord
Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent ...
pharmaphorum16d
Exact Sciences buys cancer detection company Thrive for $2.15 billion
Exact Sciences, which is behind brands Cologuard and Oncotype DX, said it will combine CancerSEEK with its scientific platform, clinical organization, and commercial infrastructure. The company ...